Genes build the future
|
|
|
- Rodger Black
- 5 years ago
- Views:
Transcription
1 Genes build the future Vivien Yang Swartz BGI Europe
2 1. Who we are? 2. What we are doing? 3. Our experiences in China 4. Our vision in Europe
3 1 Who we are? From 1% to World Leading
4 The first Human Genome Project BGI Contributed 1% International HapMap Project BGI Contributed 10% The First Asian Genome Map BGI Delegated 100% Thousand Genome Project BGI Initiated Personal Genome Project BGI version to give all new born a personal genome.
5 12 years 200 scientific research papers 58 published on top-tier international academic journals
6 Fast Company BGI Named to MIT Technology Review s Disruptive CompaniesList Recognizing World s Most Innovative Companies BGI Ranked 4th of Fast Company s 2013 The World's Top 10 Most InnovativeCompanies in China
7 BGI Model BGI Large Platform Collaborations Local Resources Globalization Bio-Gene Bank Big Science Innovation Industry
8 7 Divisions: BGI Research BGI College BGI Tech Solution BGI Diagnosis BGI Agriculture BGI Health BGI Cloud
9 2.What we are doing?
10 BGI Tech Solution Provide cross-genomics research solutions for scientists around the world Market value CNY 3.3 billion More than CNY 10 Billion after IPO within 3 years
11 BGI Diagnosis: Life Cycle Service & Partnership Public health Cancer marker, genetic testing Human leukocyte antigen genotyping Human papilloma virus genotyping Hospitals Patients Academics Pharmaceutical Life science VC Hepatitis B & C virus genotyping Inherited metabolic disorder testing Thalassemi & Leukemia genetic testing Genetic Testing Pre-implantation genetic diagnosis Rare genetic disorder testing Non-invasive chromosomal aneuploidy testing Hereditary & deafness eye diseases testing
12 BGI Diagnosis Demo case: NIFTY Non-invasive Fetal Trisomy Test 10,000 NIFTY tests have been done in Europe including Western, central, eastern European counties
13 BGI Agriculture: Provide sustainable and high-performance cultivars based on advanced-omics technologies A new industry chain of biological agriculture Modern Breeding Strategy Genome Phenotype Gene Discovery Multi-alleles engineer de novo Resequencing Function Breeding --Selection based on genome information
14 Animal Breeding Animal disease model Pigs with Alzheimers Transgenic pig: Bama mini-pigs Transgenic pig: Tibetan mini-pigs Marine Life Platform Hybrid grouper Common grouper(livedo) Conotoxin The growth rate of hybrid grouper is 3 times faster than common grouper, and it tastes better.
15 Our partners >2000 institutions, >15000 collaborators
16 BGI and the Bill & Melinda Gates to Establish Comprehensive Strategic Partnership
17 Our social responsibility Germany deadly E. coli Program June 2, 2012, BGI completed the genome sequencing and released the data; June 7, the diagnostic kit was developed and freely available worldwide
18 3. Our experiences in China
19 Case 1. National GeneBank Own by Government Manage by BGI Create open platform Integrate resources: BT + IT + Network
20 Case 2. HPV population screening Local government reimbursement Collaborated with local partners BGI provide high-through put screening solution Cover 1 Million female population 600,000 tests done
21 Case 3. Shenzhen International Biobay Establish by Shenzhen local government Create special Bio-economic Zone Apply flexible regulation system to accelerate worldclass healthcare solution development Apply flexible immigration law to attract international talent BGI s roles Key Opinion Leader Stakeholder Value Chain Integrator
22 4. Our vision in Europe
23 In country for country National healthcare system National food and agriculture system BGI Local government Centralized sequencing platform Local partner Big data Open platform Users
24 Bridging European Bio-industry with Chinese Bio-industry European company Chinese company European regulation authority European institute BGI Chinese regulation authority Chinese institute Chinese & European market
25 BGI European headquarter in Copenhagen BGI Europe A/S registered in 2010 May
26 2012 February BGI Europe Lab launch BGI and HTF co-investment 140M DKK Joint-Ph.D program with KU, AU,DTU, SDU BGI European Headquarter in Copenhagen
27 Demo case 1: GenomeDenmark From April, 2012, until next 3~5 years Sequence 1% of Danish Population (50,000) Digital BioBank for Local Clinical Genetic Researches Healthy population data for further Disease Researches Developing New Algorithm for Population data analysis
28 Demo case 2: BGI and Novo Nordisk Global Collaboration Framework Novo Nordisk and BGI jointly announced they have reached an agreement to establish a global collaboration framework, which provides an unprecedented collaborative opportunity for Novo Nordisk and BGI to accelerate their growth, execute their global partnering strategy and support disease research and development efforts. --March 2, 2012
29 BGI in Czech Republic 2012 June Get to know Czech Republic 2012 September First visit to Czech Republic 2012 December Czech Rep. delegates visit BGI Shenzhen
30 Demo case 1: GENNET BGI joint clinical lab Demo case 2: BGI and CCP collaboration
31
32 Genes build the future! Let s build the future together! Thank you
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
DiaGenic ASA Interim Report Q for early disease detection
DiaGenic ASA Interim Report Q1 2010 for early disease detection Growing market attention; Molecular diagnostics and biomarkers for Pharma HIGHLIGHTS >> Distribution agreement with Ferrer on ADtect >> First
Nanogen Epoch Biosciences Merger Frequently Asked Questions
Filed by Nanogen, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Epoch Biosciences, Inc.
A smarter healthcare system in Introducing the new Smart Plan
Product enhancements in 2016 A smarter healthcare system in 2016 Your health and wellness is at the core of everything we do. In 2016, we will continue to strengthen the healthcare system through smarter
Jefferies 2014 Global Healthcare Conference
Jefferies 2014 Global Healthcare Conference June 4 th, 2014 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the federal securities laws. This includes
IP Management Policy: A Donor s Perspective
IP Management Policy: A Donor s Perspective Zoë Ballantyne, Legal and Operations Adviser, the Wellcome Trust, U.K. Daniel Nelki, Head of Legal and Operations, the Wellcome Trust, U.K. ABSTRACT This chapter
Genomics and Insurance. 30 November 2018 Julie Scott Underwriting Proposition Manager Munich Re UKLB Tel: +44 (20)
Genomics and Insurance 30 November 2018 Julie Scott Underwriting Proposition Manager Munich Re UKLB jscott@munichre.com Tel: +44 (20) 3650 7635 0 Introduction NOCA - Genomics and Insurance - Julie Scott
Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2018 February 6, 2018
![Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2018 February 6, 2018](/thumbs/89/98907676.jpg "Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2018 February 6, 2018")
Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2018 February 6, 2018 Listed company name : Sysmex Corporation Code : 6869 Listed stock
IDEXX Laboratories Announces Second Quarter Results
FOR IMMEDIATE RELEASE Contact: Ed Garber, Director, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results Catalyst instrument placements at all-time record level of over
Contents. Part II Statements 28 Statement by Executive Board and Supervisory Board on the Annual Report 29 Independent Auditor's Reports
Annual Report 2015 Contents Part I Management Report 3 Exiqon 4 Five-Year Key Figures and Ratios 5 2015 Highlights 6 Exiqon Life Sciences 10 Exiqon Diagnostics 14 Risks 16 Financial Performance in 2015
The Funding Landscape for Small Biopharma Ventures,
HEALTHCARE The Funding Landscape for Small Biopharma Ventures, 2010-2015 Trends, strategies and priorities By Gaurav Misra Gaurav Misra Gaurav Misra specializes in pharmaceutical licensing, valuations
Molecular Diagnostic Solutions for Urologic Cancer
2018 All rights reserved 1 Molecular Diagnostic Solutions for Urologic Cancer 2017 Full Year Financial Results February 22, 2018 2 Forward Looking Statement This presentation contains forward-looking statements
Business Results Fiscal Year Ended March 31, 2018
Business Results Fiscal Year Ended March 31, 2018 Financial Highlights and Long-Term Management Goals The Sysmex Group adopted International Financial Reporting Standards () in the fiscal year ended March
APPLERA CORPORATION ANNUAL REPORT
ANNUAL REPORT 2006 A p p l i e d B i o s y s t e m s C e l e r a G e n o m i c s applera corporation consists of the following businesses: has two classes of common stock. Applera Corporation Applied Biosystems
Payer's Goals for Pre-Authorization, Medical Necessity, and Pricing for Molecular and Genetic Tests. Trisha Brown, MS, LCGC Shama Consulting, LLC
Payer's Goals for Pre-Authorization, Medical Necessity, and Pricing for Molecular and Genetic Tests Trisha Brown, MS, LCGC Shama Consulting, LLC Conflict of Interest Statement Former employee of DNA Direct,
ISPC Assessment of the Platform on Big Data revised proposal ( )
14 September 2016 ISPC Assessment of the Platform on Big Data revised proposal (2017-2022) ISPC PLATFORM RATING 1 : A 1. Summary The social value of the data and knowledge products generated by CGIAR is
Genetic testing anti-selection risk and
Genetic testing anti-selection risk and implications for insurers Florian Rechfeld Senior Research Analyst, Life & Health R&D, Swiss Re CRO Assembly, 31 th May 2018 Trends and prospects in genetic testing
Bio-Techne Releases Fourth Quarter Fiscal 2015 Results
August 6, 2015 Bio-Techne Releases Fourth Quarter Fiscal 2015 Results MINNEAPOLIS, Aug. 6, 2015 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the fourth
INTERIM REPORT - Q3 2009
INTERIM REPORT - Q3 2009 FOR EARLIER DISEASE DETECTION 2 Highlights Norwegian Research Council Names DiaGenic Most Innovative Company of the Year Highlights Scientific marketing of ADtect and BCtect started
Call title: KBBE For description of the topics of the calls, please refer to section II 'Content of calls'
Call title: KBBE 2013 For description of the topics of the calls, please refer to section II 'Content of calls' Call identifier: FP7-KBBE-2013-7 single stage Date of publication: 10 July 2012 Deadline
TABLE OF CONTENTS. 1. Introduction: The Case for Thematic Investing. 2. Global Mega Themes
Global Merces Funds Management Ltd AFSL 460 883 ACN 168 869 163 Level 5, 201 Leichhardt Street BRISBANE QLD 4000 P: +61 (2) 8117 8175 www.globalmerces.com.au MEGA TRENDS GLOBAL THEMATIC RESEARCH 2018 1
RARE-Bestpractices Conference
RARE-Bestpractices Conference 24 November 2016, Istituto Superiore di Sanità, Rome, Italy Funding relevant rare diseases research: experience from E-Rare Funding relevant rare diseases research: experience
Health System and Policies of China
of China Yang Cao, PhD Associate Professor China Pharmaceutical University Nanjing, China Transformation of Healthcare Delivery in China Medical insurance 1 The timeline of the medical and health system
June Dear Fellow Takeda Shareholder,
June 2018 Dear Fellow Takeda Shareholder, Since joining Takeda in April 2014, my mission has been to continue the transformation of Takeda in order to ensure that Takeda will be a successful company in
Invitae Corporation (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 Date of Report: May 9, 2018 (Date
Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2019 February 6, 2019
![Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2019 February 6, 2019](/thumbs/95/123620491.jpg "Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2019 February 6, 2019")
Summary of Consolidated Financial Results [ IFRS ] for the First Nine Months of the Fiscal Year Ending March 31, 2019 February 6, 2019 Listed company name : Sysmex Corporation Code : 6869 Listed stock
Healthcare in China The Opportunity for Investment. Chindex International and United Family Healthcare February 2010
Healthcare in China The Opportunity for Investment Chindex International and United Family Healthcare February 2010 Forward Looking Statements This presentation contains information which may be considered
2008 REPORT. Agreement on the breast cancer test signed with SRL Ranbaxy. Indian multi-centre breast cancer study completed
Q2 28 REPORT 1ST HALF-YEAR HIGHLIGHTS: Agreement on the breast cancer test signed with SRL Ranbaxy Indian multi-centre breast cancer study completed NOK 44.8 million share issue European patent granted
CohBar, Inc. Announces Third Quarter 2015 Financial Results
November 16, 2015 Announces Third Quarter 2015 Financial Results MENLO PARK, Calif.--(BUSINESS WIRE)-- (OTCQX: CWBR and TSX-V: COB.U), an innovative biotechnology company focused on developing mitochondria-based
IDEXX Laboratories Announces Second Quarter Results
FOR IMMEDIATE RELEASE Contact: Ed Garber, Director, Investor Relations, 1-207-556-8155 IDEXX Laboratories Announces Second Quarter Results Delivers 9% organic revenue growth and $1.10 EPS, driven by double-digit
Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results
May 3, 2016 Myriad Genetics Reports Fiscal Third-Quarter 2016 Financial Results Total Revenues of $190.5 Million Adjusted EPS of $0.41 and Diluted EPS of $0.44 Company Issues Fiscal Fourth-Quarter and
scr.zacks.com 10 S. Riverside Plaza, Chicago, IL (APDN-NASDAQ) OUTLOOK ZACKS ESTIMATES
Small-Cap Research February 13, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Applied DNA Sciences APDN: Zacks Company Report (APDN-NASDAQ) OUTLOOK
Please note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the
Please note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the presentation January 13, 2015 and should not be considered
The Digital Insurer. The Art of the Possible. 10/02/17 Avril Castagnetta, Senior Manager
The Digital Insurer The Art of the Possible 10/02/17 Avril Castagnetta, Senior Manager What if the insurance value chain Product Marketing and distribution Underwriting Policy admin Claim management Corporate
First nine months 2018
First nine months 2018 The NNIT Presenting Team PER OVE KOGUT Chief Executive Officer CARSTEN KROGSGAARD THOMSEN Chief Financial Officer KLAUS HOSBOND SKOVRUP Head of Investor Relations 2 Agenda 01 Highlights
Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases
Inotek Pharmaceuticals Announces Merger Agreement with Rocket Pharmaceuticals to Advance Pipeline of First-in-Class Gene Therapies for Rare Diseases - Company to Leverage Lentiviral and AAV Gene Therapy
IDEXX Laboratories Announces First Quarter Results
FOR IMMEDIATE RELEASE Contact: Merilee Raines, Chief Financial Officer, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, IDEXX Laboratories, Inc. (NASDAQ: IDXX), today
Payer Research Germany. Reference Studies
Payer Research Germany Reference Studies Market access & reimbursement group Market Access Environment Hereditary angioedema, adrenal insufficiency, epilepsy, Association of Statutory Health, Federal Joint
THIRD QUARTER AND 9 MONTHS BUSINESS AND FINANCIAL UPDATE
2018 THIRD QUARTER AND 9 MONTHS BUSINESS AND FINANCIAL UPDATE Forward looking statement (disclaimer) This quarterly report does not, and is not intended to, constitute or form part of, and should not be
READY TO RECODE. 37th Annual J.P. Morgan Healthcare Conference NASDAQ: BLUE 1
READY TO RECODE 37th Annual J.P. Morgan Healthcare Conference January 8, 2019 NASDAQ: BLUE NASDAQ: BLUE 1 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking
Agilent Technologies. Q3'18 Results Presentation
Agilent Technologies Q3'18 Results Presentation Safe Harbor This presentation contains forward-looking statements (including, without limitation, information and future guidance on the company s goals,
Last update: Document reference: IMI2/INT/
Last update: 07.04.2017 Document reference: IMI2/INT/2017-00830 1 Contents 1 Legal and financial framework... 3 2 IMI partners and actitivities... 4 3 Factsheet - IMI at a glance... 5 4 Budgetary principles...
Interim Report. First half of 2017, BioPorto Group. August 10, 2017 Announcement no. 10. BioPorto A/S CVR DK
Interim Report First half of 2017, BioPorto Group August 10, 2017 Announcement no. 10 BioPorto A/S CVR DK-17500317 Highlights US Clinical study commencing according to announced plan BioPorto commenced
IICCI Short Market Overviews. The Healthcare Industry in India
The Healthcare Industry in India 1. The Healthcare Industry In India healthcare is delivered through both the public sector and private sector. The public healthcare system consists of healthcare facilities
Leveraging Real-World Data and Analytics in the Device Industry. Tom Abbott Head, Healthcare Informatics Medical Device & Diagnostics
Leveraging Real-World Data and Analytics in the Device Industry Tom Abbott Head, Healthcare Informatics Medical Device & Diagnostics Agenda 1. Overview 2. What is Real World Data (RWD)? 3. How is RWD Currently
IDEXX LABORATORIES, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
Subject to Completion Preliminary Prospectus Supplement dated July 23, 2018 $400,000,000. Common Stock
The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission
GLOBAL TRANSACTIONS FORECAST
2018 GLOBAL TRANSACTIONS FORECAST Healthcare A BAKER MCKENZIE SECTOR REPORT Deal activity to surge amid strong market conditions and US tax reform Uncertainty in the wake of Brexit, the US presidential
IDEXX Laboratories Announces Third Quarter Results
FOR IMMEDIATE RELEASE Contact: Merilee Raines, Chief Financial Officer, 1-207-556-8155 IDEXX Laboratories Announces Third Quarter Results WESTBROOK, Maine, IDEXX Laboratories, Inc. (NASDAQ: IDXX), today
Weekly A-Share Picks. Oct 17, A-Share Market. (Note: This is selected translation from the Chinese version of our A-share research notes)
Weekly A-Share Picks Oct 17, 2016 (Note: This is selected translation from the Chinese version of our A-share research notes) (1) Consumer finance: Explosive growth imminent; banking, targeted platforms
Translating genetic tests from research into practice in Germany: Cascade screening for hereditary nonpolyposis colorectal cancer a model approach
CAPABILITY First Workshop May 7-9, 2007 Trolleholm Castle Jörg Schmidtke, Hannover, Germany Translating genetic tests from research into practice in Germany: Cascade screening for hereditary nonpolyposis
H Report. Medical Prognosis Institute A/S DECISION WITH PRECISION
H1 2016 Report Medical Prognosis Institute A/S DECISION WITH PRECISION August 31 st, 2016, Hoersholm, Denmark INTERIM REPORT FIRST HALF YEAR 2016 for the period January 1 st - June 30 th Highlights during
Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments
November 13, 2018 Interpace Diagnostics Reports Third Quarter 2018 Financial Results, Business Progress and Recent Accomplishments Conference Call Tuesday, November 13, 2018 at 4:30 pm ET PARSIPPANY, NJ,,
Business Results First Six Months of Fiscal Year Ending March 31, 2019
Business Results First Six Months of Fiscal Year Ending March 31, 2019 The Sysmex Group has adopted International Financial Reporting Standards (IFRS) from the fiscal year ended March 31, 2017. Figures
SPONSORED RESEARCH REVENUE: 2011/12 RESEARCH FUNDING AT ALBERTA S COMPREHENSIVE ACADEMIC AND RESEARCH INSTITUTIONS
SPONSORED RESEARCH REVENUE: 2011/12 RESEARCH FUNDING AT ALBERTA S COMPREHENSIVE ACADEMIC AND RESEARCH INSTITUTIONS October 2013 TABLE OF CONTENTS TABLE OF CONTENTS... 2 REPORT PREFACE... 3 DRIVING ALBERTA
Lazard Capital Markets 9 th Annual Healthcare Conference
Lazard Capital Markets 9 th Annual Healthcare Conference November 14, 2012 Glenn P. Muir Executive VP and CFO 1 Forward-Looking Statements This presentation contains forward-looking information that involves
Press Release SALUGGIA, MARCH 8, 2013
SALUGGIA, MARCH 8, 2013 Press Release THE BOARD OF DIRECTORS OF DIASORIN S.P.A. APPROVES THE FULL YEAR 2012 RESULTS AND THE COMPANY S DRAFT STATUTORY FINANCIAL STATEMENTS AT DECEMBER 31, 2012 At today
Tobii is the global leader in eye tracking
Nov. 3, 215 Henrik Eskilsson, CEO Esben Olesen, CFO 2 Tobii is the global leader in eye tracking World leader in eye tracking Sales per region (Jan-Sep 215) Founded in 21 Headquartered in Sweden, with
Eventide Healthcare & Life Sciences Fund
Eventide Healthcare & Life Sciences Fund Presentation June 30, 2017 8/4/17 Eventide Asset Management, LLC. 1 Eventide Funds: At A Glance Founded in 2008 Headquartered in Boston, MA Vision: to offer high
European Month of the Brain Horizon DG Research & Innovation Unit F2 Medical Research Neurosciences
European Month of the Brain Horizon 2020 DG Research & Innovation Unit F2 Medical Research Neurosciences Issues at stake of brain research Understanding the human brain and its diseases remains one of
Genetic and Molecular Lab Testing Notification/Prior Authorization Process Frequently Asked Questions Effective Nov. 1, 2017
Genetic and Molecular Lab Testing Notification/Prior Authorization Process Frequently Asked Questions Effective Nov. 1, 2017 Key Points Starting Nov. 1, 2017, notification/prior authorization is required
Business Results Fiscal Year Ended March 31, 2017
Business Results Fiscal Year Ended March 31, 2017 Financial Highlights and Mid-Term Management Plan The Sysmex Group has adopted International Financial Reporting Standards (IFRS) from the fiscal year
A Prescription for Investing in Health Care
A Prescription for Investing in Health Care HEALTH CARE SECTOR REPORT 23 October 2017 ANALYST(S) Linda D Bannister, CFA John Boylan, CFA Ashtyn Evans, CFA John Nako Buy-rated companies mentioned in this
Chr. Hansen Holding A/S Annual General Meeting November 2017
Chr. Hansen Holding A/S Annual General Meeting 2017 28 November 2017 Agenda 1. Report on the Company s activities 2. Approval of the 2016/17 Annual Report 3. Resolution on the appropriation of profit or
Sustaining long-term growth. Abcam plc Annual Report and Accounts 2017
Sustaining long-term growth Abcam plc Annual Report and Accounts 2017 Strategic report Investing for a sustainable future We are committed to serving life science researchers to achieve their mission faster.
Bio-Techne Releases Second Quarter Fiscal 2016 Results
February 2, 2016 Bio-Techne Releases Second Quarter Fiscal 2016 Results MINNEAPOLIS, Feb. 2, 2016 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second
Curetis Announces Intention to Launch Its Initial Public Offering and Listing on Euronext Amsterdam and Euronext Brussels
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, INTO OR WITHIN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE IT
Healthcare in China The Opportunity for Investment. Chindex International and United Family Healthcare November 2010
Healthcare in China The Opportunity for Investment Chindex International and United Family Healthcare November 2010 Forward Looking Statements This presentation contains information which may be considered
Executive Summary The Chal enge - Lives Are at Stake The JPIAMR The key to turn the tide of AMR
0 Executive Summary The Challenge - Lives Are at Stake Antibiotics have saved millions of lives throughout the many decades it has been in use as a common drug. However, antibiotic resistance is now a
Five-Year Financial Plan (FY2019 FY 2023) 02/23/18
Five-Year Financial Plan (FY2019 FY 2023) 02/23/18 Renewing Our Vow to the Commonwealth Six years ago, we committed to a bold vision for UK- rebuild our campus, grow funds, support faculty and staff, and
The Impact of Future Healthcare Reform on MedTech Communications
J. Robert Paulson President & CEO NxThera, Inc. The Impact of Future Healthcare Reform on MedTech Communications Perspectives From an Early-Stage Medical Device Company The Impact of Future Healthcare
FY2015 The First Half-year Results (April 1, 2015 September 30, 2015)
The First Half-year Results (April 1, 1 September 3, 1) November, 1 Please be aware of the following: * Figures and ratio in this material are rounded to the appropriate unit in principle. * The sums of
Notes to Financial Statements
26 2016 2017 Genome BC Annual Report Notes to Financial Statements 1. Operations: Genome British Columbia (the Corporation) was incorporated on July 31, 2000 under the Canada Corporations Act and continued
Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results
August 9, 2016 Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results Total Revenues of $186.5 Million Adjusted EPS of $0.36 and Diluted EPS of $0.32 Company Issues Fiscal First-Quarter 2017
Ping An Net Profit Attributable to Shareholders of Parent Company Surged 42.8% in 2017 Dividend per Share Jumped 100%
Ping An Net Profit Attributable to Shareholders of Parent Company Surged 42.8% in 2017 Dividend per Share Jumped 100% (Shanghai, Hong Kong, March 20, 2018) Ping An Insurance (Group) Company of China, Ltd.
Interim Report DiaGenic ASA
Interim Report 2011 DiaGenic ASA Highlights Business Review DiaGenic Business Strategy The goal of the company is to take a leading position in the area of blood based diagnostics within selected CNS disease
Interim Report. First Quarter 2018, BioPorto Group. May 3, 2018 Announcement no. 10. BioPorto A/S CVR DK
Interim Report First Quarter 2018, BioPorto Group May 3, 2018 Announcement no. 10 BioPorto A/S CVR DK-17500317 Highlights Important milestones in global rollout of The NGAL Test secured in first quarter
Horizon 2020 Partnerships and resulting opportunities
Horizon 2020 Partnerships and resulting opportunities W. Wittke DG Research & Innovation Partnerships and platforms in the context of Horizon 2020 Public-public partnerships (P2P): ERA-NET/ERA-NET Plus/
BCBS National Clinical Innovation Acceleration Driving Smarter, Better Healthcare in Every Local Community
BCBS National Clinical Innovation Acceleration Driving Smarter, Better Healthcare in Every Local Community Session 37, March 6, 2018 Jody Voss Vice President, Development, Innovation and Group Purchasing
INVITAE: Genetics from downstream to mainstream Q CONFERENCE CALL
INVITAE: Genetics from downstream to mainstream Q2 2017 CONFERENCE CALL Safe harbor statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
ALLIANCE DOUBLE PLUS VITAL ESSENTIAL FIRST CHOICE NETWORK CHOICE
HOSPITAL ACCOMMODATION INCLUDING CONFINEMENTS SUBJECT TO PRE-AUTHORISATION ATTENDING DOCTORS AND SPECIALISTS CONSULTATIONS MEDICAL AND SURGICAL PROCEDURES INCLUDING CONFINEMENTS AUXILIARY HEALTHCARE IN
ECONOMIC INCENTIVES FOR THE DEVELOPMENT OF PUERTO RICO. Act No. 73 of May 28, William Riefkohl
ECONOMIC INCENTIVES FOR THE DEVELOPMENT OF PUERTO RICO Act No. 73 of May 28, 2008 William Riefkohl New Incentives Act Historical Perspective 60 years of industrial incentives program Expiration of previous
Approver: Dr. Robert Steiner Executive Director, Marshfield Clinic Research Foundation
Policy # 1024.1(previous number) Policy Title: Effective Date: mm/dd/yyyy Supersedes: N/A Approver: Dr. Douglas Reding Vice President, Marshfield Clinic Date Approver: Dr. Robert Steiner Executive Director,
Zacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial Comprehensive March 28, 2019 John D. Vandermosten, CFA 312-265-9588 / jvandermosten@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606
MATERIAL TRANSFER AGREEMENT FOR TRANSFER OF MATERIALS TO NCRAD
MATERIAL TRANSFER AGREEMENT FOR TRANSFER OF MATERIALS TO NCRAD This Master Material Transfer Agreement for Transfer of Materials to NCRAD ( Master Agreement ) is made and entered into by and between The
Introduction to QTL (Quantitative Trait Loci) & LOD analysis Steven M. Carr / Biol 4241 / Winter Study Design of Hamer et al.
Introduction to QTL (Quantitative Trait Loci) & LOD analysis Steven M. Carr / Biol 4241 / Winter 2016 Quantitative Trait Loci: contribution of multiple genes to a single trait Linkage between phenotypic
IDEXX Laboratories Announces First Quarter Results
FOR IMMEDIATE RELEASE Contact: Merilee Raines, Chief Financial Officer, 1-207-556-8155 IDEXX Laboratories Announces First Quarter Results WESTBROOK, Maine, IDEXX Laboratories, Inc. (NASDAQ: IDXX), today
Company Update. 2018
Company Update. 2018 Volition Update 2018 Our Mission The dedicated team at Volition is a collective force of distinct individuals with a shared goal to save lives by revolutionizing the way disease, and
TBG Diagnostics Limited
TBG Diagnostics Limited (formerly Progen Pharmaceuticals Limited) Annual Report TBG Diagnostics Limited (formerly Progen Pharmaceuticals Limited) TBG Diagnostics Limited Annual Report Contents 1 Chairman
Inno-Gene S.A. Fair value: PLN 9.60 Update Rating: n.a.
Inno-Gene S.A. Fair value: PLN 9.60 Update Rating: n.a. In 9M/16, Inno-Gene (IGN) generated sales of PLN 3.6m (+5.9% y-o-y). Due to a significantly higher share of personnel costs and D&A expenses EBIT
Presentation to UBS Australasia Conference November Attached presentation delivered by nib at the UBS Australasia Conference (8 November 2016).
nib holdings limited Head Office 22 Honeysuckle Drive Newcastle NSW 2300 abn 51 125 633 856 t 13 14 63 f 02 4925 1999 e nib@nib.com.au w nib.com.au 8 November 2016 The Manager Company Announcements Australia
TELECONFERENCE Q May 2015
TELECONFERENCE Q1 2015 6 May 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
ANNUAL REPORT 2005 ILLUMINA INC 2005 A N N U A L REP O R T
ANNUAL REPORT 2005 3404124 Illumina helps researchers understand the genetic basis of disease. Shown on the cover are Sentrix HumanHap BeadChips, each of which can genotype hundreds of thousands of SNPs
QIAGEN N.V. Annual Report 2000
QIAGEN N.V. Annual Report 2000 Contents 2 Report of the Supervisory Board 6 QIAGEN Keys to the Life Science Revolution 4 Letter from the Management Board 16 Contents Financial Data QIAGEN is the world
METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)
METHODOLOGY NOTES TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO) Country of Disclosure: United Kingdom Year of Disclosure: 2017
County of St. Clair Option 1. Benefits-at-a-Glance
Medicare Plus Blue SM Group PPO Medical Benefits with Prescription Drugs County of St. Clair Option 1 Benefits-at-a-Glance January 1, 2019 - December 31, 2019 The information provided is a Summary of Benefits.
William Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles
William Blair 35 th Annual Growth Stock Conference June 9, 2015 Copyright 2014 Quintiles NYSE: Q Forward Looking Statements and Use of Non-GAAP Financial Measures This presentation contains forward-looking
QIAGEN reports results for third quarter and first nine months of 2018
QIAGEN reports results for third quarter and first nine months of 2018 Q3 2018 results exceed targets as QIAGEN on track to achieve 2018 goals: o sales of $377.9 million +3.8% reported (+6.5% at constant
Please note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the
Please note that the following presentation contains financial projections and other forward-looking statements that are specific to the date of the presentation July 16, 2012 and should not be considered
2013 Annual Letter to Shareholders. Fellow Shareholders:
2013 Annual Letter to Shareholders Fellow Shareholders: In our 2012 Annual Letter to Shareholders, we ended with the following statement. The current market is one in which to be investing, not harvesting.